Table 1 Weights and Echocardiographic parameters in all studied groups.

From: Melatonin enhances captopril mediated cardioprotective effects and improves mitochondrial dynamics in male Wistar rats with chronic heart failure

Groups

Parameters

Group I (control)

Group II (ISO)

Group III (ISO + captopril)

Group IV (ISO + melatonin)

Group V (ISO + melatonin + captopril)

Body weight (g)

Mean ± SD

229.8 ± 10.2

219.1 ± 10.8

228.8 ± 8.6

222.2 ± 10.5

228.1 ± 8.8

 

p value

 

p > 0.05a

p > 0.05a,b

p > 0.05a,b,c

p > 0.05a,b,c,d

Heart weight (g)

Mean ± SD

1.12 ± 0.09

1.73 ± 0.11

1.43 ± 0.11

1.57 ± 0.08

1.28 ± 0.06

 

p value

 

p < 0.001a

p < 0.001a,b

p < 0.001a,b

p < 0.001a,b,d

     

p < 0.01c

p < 0.01c

HWI (mg/g)

Mean ± SD

4.89 ± 0.6

7.9 ± 0.43

6.24 ± 0.37

7.06 ± 0.24

5.61 ± 0.16

 

p value

 

p < 0.001a

p < 0.001a,b

p < 0.001a,b,c

p < 0.001a,b,c,d

LVEDD (mm)

Mean ± SD

5.33 ± 0.42

8.92 ± 0.63

7.14 ± 0.56

8.04 ± 0.55

6.26 ± 0.53

 

p value

 

p < 0.001a

p < 0.001a,b

p < 0.001a,b,c

p < 0.01a,b,c,d

LVESD (mm)

Mean ± SD

3.1 ± 0.40

7.03 ± 0.6

5.01 ± 0.56

5.99 ± 0.51

4.11 ± 0.47

 

p value

 

p < 0.001a

p < 0.001a,b

p < 0.001a,b,c

p < 0.001a,b,c,d

LVFS %

Mean ± SD

42 ± 3.12

21.3 ± 1.33

30 ± 2.44

25.6 ± 1.34

34.4 ± 2.45

 

p value

 

p < 0.001a

p < 0.001a,

p < 0.001a,b,c

p < 0.001a,b,c,d

LVEF %

Mean ± SD

72.4 ± 3.83

41.3 ± 2.4

55.9 ± 4.06

48.7 ± 2.4

62.4 ± 3.65

 

p value

 

p < 0.001a

p < 0.001a,b

p < 0.001a,b,c

p < 0.001a,b,c,d

  1. SD (standard deviation), a = versus group I, b = versus group II, c = versus group III; d = versus group IV. (HWI) heart weight index, LVEDD; left ventricular End diastolic dimension, LVESD; left ventricular End systolic dimension, LVFS; left ventricular fractional shortening, LVEF; left ventricular ejection fraction.